


STX-0119

Cat. No.:	HY-103692
CAS No.:	851095-32-4
Molecular Formula:	C ₂₂ H ₁₄ N ₄ O ₃
Molecular Weight:	382.37
Target:	STAT
Pathway:	JAK/STAT Signaling; Stem Cell/Wnt
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 13.33 mg/mL (34.86 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent		1 mg	5 mg	10 mg
	Concentration	Mass			
	1 mM		2.6153 mL	13.0763 mL	26.1527 mL
	5 mM		0.5231 mL	2.6153 mL	5.2305 mL
	10 mM		0.2615 mL	1.3076 mL	2.6153 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC₅₀ of 74 μM^[1].

IC₅₀ & Target

STAT3
74 μM (IC₅₀, STAT3 transcription)

In Vitro

STX-0119 (10-50 μM; 24 h) inhibits STAT3 dimerization through a direct interaction with the STAT3 protein and not via the modulation of upstream regulators such as JAK in HEK293 and MDA-MB-468 cells^[1].
STX-0119 (10-50 μM; 24 h) reduces the expression of STAT3 target proteins^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis^[1]

Cell Line:	MDA-MB-468 cells
Concentration:	10, 20 and 50 μM
Incubation Time:	24 h

Result:	Reduced the expression of STAT3 target proteins, namely, c-myc, cyclin D1, and survivin, in a concentration-dependent manner. Did not suppress the expression of those STAT3-regulated oncoproteins.
---------	--

In Vivo

STX-0119 (160 mg/kg; oral gavage; daily for 4 days) inhibits SCC-3 tumor growth in mice^[1].
The plasma concentration of STX-0119 (160 mg/kg; oral gavage) is maintained at >100 µg/mL (>260 µM), even at 8 h after administration^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male BALB/cA-v/v nude mice, SCC-3 lymphoma xenograft model ^[1]
Dosage:	160 mg/kg
Administration:	Oral gavage, daily for 4 days
Result:	Suppressed the growth of SCC-3 cells significantly on the fourth day.

REFERENCES

[1]. Matsuno K, et al. Identification of a New Series of STAT3 Inhibitors by Virtual Screening. ACS Med Chem Lett. 2010 Jul 13;1(8):371-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA